TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 G328V mutant (unknown origin) expressed in HEK293 cells incubated for 2 hrs by Na...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 Q207D mutant (unknown origin) expressed in HEK293 cells incubated for 2 hrs by Na...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of ALK2 G328V mutant (unknown origin) by radiometric assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of human ALK2 R206H mutant using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 R206H mutant (unknown origin) expressed in HEK293 cells incubated for 2 hrs by Na...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of ALK2 R258G mutant (unknown origin) by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of human ALK1 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 G356D mutant (unknown origin) expressed in HEK293 cells incubated for 2 hrs by Na...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 19nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 28nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 31nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 39nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetEpithelial discoidin domain-containing receptor 1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 41nMAssay Description:Inhibition of DDR1 (unknown origin)More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 42nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 45nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 47nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 49nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 54nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 56nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 57nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 59nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 67nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 67nMAssay Description:Inhibition of human ALK2 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 68nMAssay Description:Inhibition of human ALK6 using casein as substrate in presence of [gamma-33P]-ATP by radiometric hotspot assayMore data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
Ontario Institute For Cancer Research
Curated by ChEMBL
Ontario Institute For Cancer Research
Curated by ChEMBL
Affinity DataIC50: 73nMAssay Description:Competitive displacement of PBI-6908 from nanoluciferase-fused ALK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET NanoGl...More data for this Ligand-Target Pair